NCT00514865

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 278 (actual)
• Sponsor: Ono Pharma USA Inc · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	ONO-2333Ms Experimental 2	5-10 mg QD(once a day) for 8 weeks
DRUG	Placebo	0 mg QD(once a day) for 8 weeks
DRUG	ONO-2333Ms Experimental 1	1-2 mg QD(once a day) for 8 weeks

Timeline

• Start date: 2007-06-13
• Primary completion: 2008-04-01
• Completion: 2008-06-01
• First posted: 2007-08-10
• Last updated: 2023-11-28

Locations

1 site across 1 country: United States